SCHEMBL15230910

SCHEMBL15230910

Cn1c(=O)[nH]c2c(Br)cccc2c1=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 2/20 0.54
ADORA2B P29275 2/20 0.54
ADORA2A P29274 1/20 0.54
ADORA1 P30542 1/20 0.54
CA12 O43570 3/20 0.44
CA9 Q16790 3/20 0.44
CA1 P00915 2/20 0.44
CA2 P00918 2/20 0.44
ENPP3 O14638 1/20 0.43
ENPP1 P22413 1/20 0.43
PDE7A Q13946 2/20 0.43
KDM4E B2RXH2 1/20 0.42
HSD17B10 Q99714 1/20 0.42
FEN1 P39748 5/20 0.41
CSNK2A2 P19784 1/20 0.41
CSNK2B P67870 1/20 0.41
CSNK2A1 P68400 1/20 0.41
CDK4 P11802 2/20 0.40
CCND1 P24385 2/20 0.40
ERCC1 P07992 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15230610 0.83 CA12 (0.54) ADORA3ADORA2BADORA2AADORA1CA12
SCHEMBL17268469 0.80 ADORA2B (0.45) ADORA3ADORA2BADORA2AADORA1HSD17B10
SCHEMBL15231207 0.79 ALDH1A1 (0.45) CA12CA9CA1CA2ENPP3
SCHEMBL15230881 0.79 CYP1A2 (0.58) ADORA3ADORA2BADORA2ACA12CA9
SCHEMBL7884503 0.79 RXFP1 (0.47) ADORA3ADORA2BADORA2AADORA1CA12
SCHEMBL25544426 0.77 ADORA2B (0.44) ADORA3ADORA2BADORA2AADORA1PDE7A
SCHEMBL15230468 0.75 CA12 (0.42) CA12CA9CA1CA2KDM4E
SCHEMBL26127488 0.75 DDR1 (0.46) ADORA3ADORA2BADORA2AADORA1CA12
SCHEMBL30682855 0.75 DDR1 (0.46) ADORA3ADORA2BADORA2AADORA1CA12
SCHEMBL6389551 0.74 FEN1 (0.50) ADORA3ADORA2BADORA2AADORA1FEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9394297-B2 Amides as pim inhibitors AMGEN INC. (US) 2016-07-19 US disclosed
US-9394297-B2 Amides as pim inhibitors AMGEN INC. (US) 2016-07-19 US disclosed
US-9394297-B2 Amides as pim inhibitors AMGEN INC. (US) 2016-07-19 US disclosed
US-20150329538-A1 AMIDES AS PIM INHIBITORS AMGEN INC. (US) 2015-11-19 US disclosed
US-20150329538-A1 AMIDES AS PIM INHIBITORS AMGEN INC. (US) 2015-11-19 US disclosed
US-20150329538-A1 AMIDES AS PIM INHIBITORS AMGEN INC. (US) 2015-11-19 US disclosed
WO-2013130660-A1 AMIDES AS PIM INHIBITORS AMGEN INC. (US) 2013-09-06 WO disclosed
WO-2013130660-A1 AMIDES AS PIM INHIBITORS AMGEN INC. (US) 2013-09-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150329538-A1 AMIDES AS PIM INHIBITORS PIM1, PIM3, PIM2 ADORA3 3404/4885ADORA2B 4430/4885ADORA2A 4334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.